HER2-Specific CAR-Modified Virus-Specific T Cells for Progressive Glioblastoma

This open-label phase 1 dose-escalation study examines whether systemic administration of HER2-specific chimeric antigen receptor–modified virus-specific T cells is safe and whether these cells have antiglioblastoma activity.

http://ift.tt/2o81UU3